Distribution of LDL-C Reduction with Atorvastatin, Rosuvastatin and Simvastatin: A VOYAGER Meta-Analysis

被引：0
|
作者：
Karlson, Bjorn W. [1 ,2 ]
Palmer, Michael K. [3 ]
Nicholls, Stephen J. [4 ]
Lundman, Pia [5 ]
Barter, Philip J. [6 ]
机构：
[1] AstraZeneca, Molndal, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Dept Mol & Clin Med, Gothenburg, Sweden
[3] Manchester Metropolitan Univ, Sch Healthcare Sci, Manchester M15 6BH, Lancs, England
[4] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[5] Karolinska Inst, Danderyd Hosp, Stockholm, Sweden
[6] Univ New S Wales, Sydney, NSW, Australia
来源：
CARDIOLOGY | 2015年 / 131卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-06
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [21] Effects of Atorvastatin and Rosuvastatin on Renal Function: A Meta-analysis
    Savarese, Gianluigi
    Musella, Francesca
    Volpe, Massimo
    Paneni, Francesco
    Perrone-Filardi, Pasquale
    CIRCULATION, 2012, 126 (21)
  • [22] Effects of Rosuvastatin and Atorvastatin on Renal Function - Meta-Analysis
    Wu, Yongxia
    Wang, Yan
    An, Chuankai
    Dong, Zhe
    Liu, Hui
    Zhang, Yun
    Zhang, Mingxiang
    An, Fengshuang
    CIRCULATION JOURNAL, 2012, 76 (05) : 1259 - 1266
  • [23] EFFECTIVENESS OF ATORVASTATIN, PRAVASTATIN AND SIMVASTATIN IN THE REDUCTION OF CARDIOVASCULAR EVENTS: AN INDIRECT COMPARISON META-ANALYSIS
    Ribeiro, R. A.
    Stella, S. F.
    Vieira, J. L. C.
    Restelatto, L. M. F.
    Polanczyk, C. A.
    VALUE IN HEALTH, 2009, 12 (07) : A313 - A314
  • [24] Achievement of the european atherosclerosis society LDL-C target by hypercholesterolaemic patients receiving rosuvastatin compared to atorvastatin, pravastatin or simvastatin: An evidence-based medicine approach
    Morrell, J
    Edwards, S
    VALUE IN HEALTH, 2003, 6 (03) : 310 - 310
  • [25] PERCENT OF PATIENTS ATTAINING EUROPEAN GUIDELINES LDL-C GOAL OF <2 MMOL/L IN 3 STUDIES EVALUATING EZETIMIBE/SIMVASTATIN VERSUS ATORVASTATIN OR ROSUVASTATIN
    Brudi, P.
    Lantz, K.
    Polis, A.
    Tershakovec, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 188 - 188
  • [26] Cost of Treating to a Modified European Atherosclerosis Society LDL-C TargetComparison of Atorvastatin with Fluvastatin, Pravastatin and Simvastatin
    D. G. Smith
    S. J. Leslie
    T. D. Szucs
    S. McBride
    L. M. Campbell
    C. Calvo
    J.-M. Lecerf
    R. Fellin
    Clinical Drug Investigation, 1999, 17 : 185 - 193
  • [27] Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering A Systematic Review and Meta-analysis
    Navarese, Eliano P.
    Robinson, Jennifer G.
    Kowalewski, Mariusz
    Kolodziejczak, Michalina
    Andreotti, Felicita
    Bliden, Kevin
    Tantry, Udaya
    Kubica, Jacek
    Raggi, Paolo
    Gurbel, Paul A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (15): : 1566 - 1579
  • [28] Impact of Bempedoic acid on LDL-C reduction and cardiovascular outcomes: A comprehensive meta-analysis of randomized controlled trials
    Del Carpio-Tenorio, Cristian
    Llerena-Velastegui, Jordan
    Villacis-Lopez, Cecibel
    Placencia-Silva, Marcela
    Santander-Fuentes, Carolina
    Benitez-Acosta, Karen
    Sanahuja-Montiel, Cristian
    Dominguez-Gavilanes, Daniel
    Carrasco-Perez, Paul
    Calderon-Lopez, Carlos
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (02)
  • [29] LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation
    Sathyapalan, T.
    Atkin, S. L.
    Kilpatrick, E. S.
    ANNALS OF CLINICAL BIOCHEMISTRY, 2015, 52 (01) : 180 - 182
  • [30] A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy
    Alder, Madeleine
    Bavishi, Aakash
    Zumpf, Katelyn
    Peterson, Jonna
    Stone, Neil J.
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (11): : 1322 - 1327
12345